The Latest Cardiac and Vascular News
Benefits of transvenous implantable defibrillators, including anti-tachycardia pacing (ATP), in a single device implanted safely outside the vascular space: 77% ATP success rate, in line with transvenous ICDs Avoided shocks in nearly half of all ventricular tachycardia/ventricular fibrillation (VT/VF) episodes […]
MARLBOROUGH, Mass., March 12, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced key data presentations that will be featured at the annual congress of the European Heart Rhythm Association (EHRA) in Barcelona, Spain, on March 18-20. Notably, there will be three late-breaking clinical trials […]
SILVER SPRING, Md.–(BUSINESS WIRE)– Aziyo Biologics, a fully integrated regenerative medicine company, today announced the launch of a new CanGaroo Bio Envelope specifically for use with subcutaneous implantable cardioverter-defibrillators (S-ICDs). This is the only cardiac implantable electronic device (CIED) envelope available for use with […]
MARLBOROUGH, Mass., Sept. 25, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) has launched the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the HeartLogic Heart Failure Diagnostic to help physicians improve heart failure (HF) management. […]
ABBOTT PARK, Ill., Sept. 22, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for one of Abbott’s most widely-used implantable cardioverter defibrillators (ICD) and associated high voltage leads. The approval of […]
MARLBOROUGH, Mass., May 9, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. The approval includes new features […]
